ClinicalTrials.gg
RecruitingNCT05290129Updated Apr 6, 2026

Oxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study

An interventional study of Oxytocin in Postpartum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies testing oxytocin in Postpartum Hemorrhage — 8 open to participants now, 9 under way, 1 of them phase 3. Oxytocin · Postpartum Hemorrhage.

Planned enrollment
45th of 64
40 · median 108
Started
2022
with 3 others
No phase
37 of 64
6 open now
Registered
51st of 64
by date
Lead sponsor
22 of 64
Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Among the 64 studies testing oxytocin in Postpartum Hemorrhage, this one is the 45th largest by planned enrollment, is one of 4 that started in 2022, is one of 37 with no phase, and was the 51st registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 64 studies testing oxytocin in Postpartum Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About oxytocin

Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing oxytocin in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient.

The investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU/min (44 IU/h), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.

Read the detailed description

This study will be conducted as a prospective, double blinded clinical trial (patient, anesthesiologist and obstetrician blinded to the oxytocin dose), in an up-down sequential allocation fashion. The objective of the study is to determine the minimum effective dose of oxytocin infusion required to produce appropriate uterine contraction during and after cesarean delivery under neuraxial anesthesia in laboring women. For the purpose of this study, the minimum effective dose is defined to be that at which adequate response occurs in 90% of patients, i.e. ED90.

03

Conditions studied

  • Postpartum Hemorrhage

Browse trials for

Keywords

  • Cesarean delivery
  • oxytocin
  • uterotonic
  • pregnancy
  • labour
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with induced or augmented labour undergoing cesarean delivery under neuraxial anesthesia (at least 3 hours of prior exposure to oxytocin during labour)

Exclusion criteria

Exclusion Criteria:

  • All patients who refuse to give written
  • All patients who declare allergy or to oxytocin
  • A history of hypertension and/or severe cardiac disease(s)
  • All patients who have for neuraxial anesthesia
  • All patients who will be converted to general anesthesia intraoperatively
  • All patients with placenta previa and multiple gestation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Oxytocin infusion rate 4 IU/h

    The maintenance infusion rate of oxytocin will be 4 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 6 IU/h

    The maintenance infusion rate of oxytocin will be 6 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 10 IU/h

    The maintenance infusion rate of oxytocin will be 10 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 14 IU/h

    The maintenance infusion rate of oxytocin will be 14 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 18 IU/h

    The maintenance infusion rate of oxytocin will be 18 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 22 IU/h

    The maintenance infusion rate of oxytocin will be 22 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 26 IU/h

    The maintenance infusion rate of oxytocin will be 26 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 30 IU/h

    The maintenance infusion rate of oxytocin will be 30 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 34 IU/h

    The maintenance infusion rate of oxytocin will be 34 IU/h.

    Drug: Oxytocin

  • Experimental
    Oxytocin infusion rate 36 IU/h

    The maintenance infusion rate of oxytocin will be 36 IU/h.

    Drug: Oxytocin

Interventions

  • Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

    Also known as: Pitocin

06

What researchers measure

Primary outcomes

  1. Uterine tone up to discharge from the post anesthetic care unit (PACU): questionnaire

    Uterine tone will be evaluated as satisfactory or unsatisfactory by the obstetrician throughout the surgery, starting at 5 minutes after the oxytocin infusion. It will also be measured at 10 minutes following the oxytocin infusion and every 10 minutes following that for the duration of the surgery. Unsatisfactory uterine tone at any time until discharge from the PACU will be considered a failure of the maintenance infusion.

    Time frame: 2 hours

Secondary outcomes

  1. Calculated blood loss

    Estimated blood loss will be calculated using the difference in hematocrit values prior to surgery and 24 hours post surgery, using the following formula: Calculated blood loss (mL) = EBV ((Pre-op Htc-Post-op Htc)/pre-op Htc) EBV (estimated blood volume) in ml: patient's weight in kg x 85.

    Time frame: 24 hours

  2. Need for blood transfusion

    Blood product administered.

    Time frame: 24 hours

  3. Episodes of bleeding postpartum

    Number of episodes of bleeding postpartum up to 24 hours post delivery.

    Time frame: 24 hours

  4. Intraoperative requirement for additional uterotonic medication

    A request made by the obstetrician performing the cesarean delivery for additional uterotonic medication, due to bleeding or poor uterine tone.

    Time frame: 1 hour

  5. Requirement for additional uterotonic medication in the PACU

    Any uterotonic medication administered while the patient is in PACU

    Time frame: 2 hours

  6. Requirement for additional uterotonic medication from discharge from the PACU until 24 hours postpartum.

    Any uterotonic medication administered after the patient is discharged from PACU until 24 hours postpartum.

    Time frame: 24 hours

  7. Hypotension: systolic blood pressure less than 80% of baseline

    Systolic blood pressure \< 80% of baseline, from drug administration until end of surgery

    Time frame: 2 hours

  8. Hypertension: systolic blood pressure greater than 120% of baseline

    Systolic blood pressure \> 120% of baseline, from drug administration until end of surgery

    Time frame: 2 hours

  9. Tachycardia: heart rate greater than 130% of baseline

    Heart rate \> 130% of baseline, from drug administration until end of surgery

    Time frame: 2 hours

  10. Bradycardia: heart rate less than 70% of baseline

    Heart rate \< 70% of baseline or a heart rate \< 50bpm, from drug administration until end of surgery

    Time frame: 2 hours

  11. Presence of ventricular tachycardia: ECG

    Presence of ventricular tachycardia as recorded by ECG, from drug administration until end of surgery

    Time frame: 2 hours

  12. Presence of atrial fibrillation: ECG

    Presence of atrial fibrillation as recorded by ECG, from drug administration until end of surgery

    Time frame: 2 hours

  13. Presence of atrial flutter: ECG

    Presence of atrial flutter as recorded by ECG, from drug administration until end of surgery

    Time frame: 2 hours

  14. Presence of nausea: questionnaire

    The presence of nausea and number of episodes, from drug administration until end of surgery, as reported by the patient

    Time frame: 2 hours

  15. Presence of vomiting: questionnaire

    The presence of vomiting and number of episodes, from drug administration until end of surgery

    Time frame: 2 hours

  16. Presence of chest pain: questionnaire

    Any presence of chest pain, from drug administration until end of surgery, as reported by the patient

    Time frame: 2 hours

  17. Presence of shortness of breath: questionnaire

    Any presence of shortness of breath, from drug administration until end of surgery, as reported by the patient

    Time frame: 2 hours

  18. Presence of headache: questionnaire

    Any presence of headache, from drug administration until end of surgery, as reported by the patient

    Time frame: 2 hours

07

Study locations

1 of 1 sites recruiting
  • Mount Sinai Hospital
    Toronto, Ontario M5G1X5, Canada
    Recruiting
    • Mrinalini Balki, MD · Contactmrinalini.balki@uhn.ca · 416-586-4800
    • Genevieve Lachance, MD · Sub investigator
    • Jose Carvalho, MD · Sub investigator
    • Jackie Thomas, MD · Sub investigator
    • Kristi Downey, MSc · Sub investigator
    • Atsuko Hirano, MD · Sub investigator
    • Xiang Y Ye, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 52 months is above that.

Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2022
First posted
Mar 22, 2022
StartActual
Aug 17, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05290129
Responsible party
Sponsor
First posted
Mar 22, 2022
Start date
Aug 17, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Mrinalini Balki, MD
Contact
mrinalini.balki@uhn.ca
416-586-4800 ext. 5270
Mrinalini Balki, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion